Experimental Huntington’s disease drug can be given less frequently

Experimental Huntington’s disease drug can be given less frequently

Publication date: Jul 02, 2019

An experimental drug for Huntington’s disease from Carlsbad’s Ionis Pharmaceuticals appears to be more long-lasting than previously thought.

Roche announced the trial’s resumption to the Huntington’s disease community on June 20, according to the blog of Kenneth Serbin, who carries the mutation.

New information from an earlier trial indicated that the drug, RG6042, showed the same signs of potential efficacy when given every two months, as when given every month.

“We believe this change to the pivotal study design will greatly simplify the operation of the study and ease the burden on study sites and patients, as less frequent dosing is more manageable for patients and physicians,” Frank Bennett, senior vice president of research at Ionis, said by email.

Concepts Keywords
Basal Ganglia Ionis Pharmaceuticals
Brain Huntington’s disease
Carlsbad Pharmaceutical industry
Clinical Trial Drug discovery
Drug Therapy Spinal muscular atrophy
Genetic Disease Antisense RNA
Huntington Pharmaceutical sciences
Lumbar Puncture Health
Mutant Drug therapy
Mutation Movement thinking disorders
Neurons Fatal genetic disease
Papal Audience Potential substantial disease
Placebo Clinical trial
Pope Francis
San Diego
Swiss

Semantics

Type Source Name
gene UNIPROT CEP55
gene UNIPROT RNMT
gene UNIPROT MET
gene UNIPROT SLTM
drug DRUGBANK Methionine
gene UNIPROT NAA50
disease MESH community
gene UNIPROT SELL
disease DOID genetic disease
disease MESH genetic disease

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *